Nav: Home

Publication details IDRI's promising leprosy vaccine candidate

April 26, 2018

A publication in Nature Partner Journals (npj) Vaccines indicates that post-exposure prophylaxis with LepVax, IDRI's leprosy vaccine candidate, not only appears safe but, unlike BCG (a tuberculosis vaccine that provides some protection against leprosy), alleviates and delays the neurologic disruptions caused by Mycobacterium leprae infection in nine-banded armadillos. This is an important finding because armadillos are the only other host of M. leprae that closely recapitulates many of the structural, physiological and functional aspects of leprosy observed in humans, including progressive and irreversible nerve damage.

Characterized by the World Health Organization as a "neglected tropical disease," leprosy (also known as Hansen's disease) is caused by Mycobacterium leprae. Nearly a quarter of a million people are diagnosed with leprosy each year, with the infection progressing to cause disfiguration of the skin and mucous membranes as well as progressive and irreversible nerve damage. While drug therapy exists for leprosy, it must be taken for many months, has many side effects and often is given too late to prevent the damage caused by the bacterial infection that leads to lifelong disability.

"This report demonstrates the selection and advancement of the first defined subunit vaccine - LepVax -- developed specifically for leprosy," said Malcolm Duthie, PhD, a senior scientist at IDRI. IDRI and The National Hansen's Disease Laboratories (NHDP), under a research agreement with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, conducted mouse experiments to demonstrate that the vaccine is immunogenic and can interrupt M. leprae infection. They also developed cutting edge neurological methods in nine-banded armadillos that were used to evaluate the effect of LepVax on nerve injury as an innovative advance to the field. "Our results indicate that post-exposure immunization in nine-banded armadillos was not only safe but limited and delayed nerve damage," Duthie added.

In stark contrast to BCG, which precipitated rapid and severe motor nerve conduction abnormalities in previously infected armadillos, motor nerve injury was appreciably delayed in armadillos treated three times at monthly intervals with LepVax. The data supported a successful Investigational New Drug (IND) application with the U.S. Food & Drug Administration, allowing advancement of LepVax into a Phase 1 clinical trial in humans in the U.S.
-end-
"These data highlight the need for continued leprosy research and the importance of both private and public funding as we seek new solutions for neglected tropical diseases, such as leprosy," said Duthie. This research was funded by grants from the American Leprosy Missions, Order of Malta (MaltaLep), The Heiser Program for Research in Leprosy and Tuberculosis of The New York Community Trust, Renaissance Health Service Corporation, and a National Institutes of Health, National Institute of Allergy and Infectious Diseases supported interagency agreement with the Health Resources and Services Administration's National Hansen's Disease Program (AAI15006-004-00000).

About IDRI: As a nonprofit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world. For more information, visit http://www.idri.org.

Infectious Disease Research Institute

Related Vaccine Articles:

Who should get the COVID-19 vaccine first?
Nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution -- called the Fair Priority Model -- which aims to reduce premature deaths and other irreversible health consequences from COVID-19.
Breakthrough with cancer vaccine
Scientists have developed a new cancer vaccine with the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers.
How to improve the pneumococcus vaccine
Pneumococcus kills 1 million children annually according to the World Health Organization.
US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.
Successful MERS vaccine in mice may hold promise for COVID-19 vaccine
In a new study, published April 7 in mBio, researchers from the University of Iowa and the University of Georgia demonstrate that a new vaccine fully protects mice against a lethal dose of MERS, a close cousin of COVID-19.
Coronavirus Vaccine: Where are we and what's next? (video)
You might have heard that COVID-19 vaccine trials are underway in Seattle.
Why isn't there a vaccine for staph?
A study from Washington University School of Medicine in St.
Exposing vaccine hesitant to real-life pain of diseases makes them more pro-vaccine
New research from Brigham Young University professors finds there is a better way to help increase support for vaccinations: Expose people to the pain and suffering caused by vaccine-preventable diseases instead of trying to combat people with vaccine facts.
Lifetime flu vaccine?
Another year, another flu vaccine because so far scientists haven't managed to make a vaccine that protects against all strains of flu.
On the horizon: An acne vaccine
A new study published in the Journal of Investigative Dermatology reports important steps that have been taken towards the development of an acne vaccine.
More Vaccine News and Vaccine Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.